Randomized trials: experience of the intergroupe francais du myelome

Authors
Attal, M Harousseau, JL
Citation
M. Attal et Jl. Harousseau, Randomized trials: experience of the intergroupe francais du myelome, B CANCER, 88(9), 2001, pp. 888-892
Citations number
12
Categorie Soggetti
Oncology
Journal title
BULLETIN DU CANCER
ISSN journal
00074551 → ACNP
Volume
88
Issue
9
Year of publication
2001
Pages
888 - 892
Database
ISI
SICI code
0007-4551(200109)88:9<888:RTEOTI>2.0.ZU;2-M
Abstract
This article summarizes the different clinical results of the IFM trials: h igh dose therapy supported with autologous stem cells improves survival, me lphalan 200 mg/m(2) is the best preparative regimen, unpurged peripheral bl ood stem cells are the recommended source of stem-cells to support high dos e therapy, tandem transplants significantly improve survival. However, desp ite these encouraging results, long term survival needs inovative strategie s evaluated with the current IFM 99 protocol.